|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Zantac
|
|
gptkbp:activities
|
sodium channel blocker
|
|
gptkbp:appointed_by
|
injection
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
1950s
|
|
gptkbp:brand
|
gptkb:Procanbid
gptkb:Pronestyl
|
|
gptkbp:category
|
Category C
|
|
gptkbp:class
|
antiarrhythmic agent
|
|
gptkbp:clinical_trial
|
Phase IV
cardiac arrhythmias
|
|
gptkbp:contraindication
|
severe heart failure
heart block
|
|
gptkbp:developed_by
|
gptkb:A._H._Robins_Company
|
|
gptkbp:dosage_form
|
gptkb:tablet
500 mg
injection
250 mg
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
procainamide
|
|
gptkbp:indication
|
gptkb:atrial_fibrillation
gptkb:ventricular_tachycardia
premature ventricular contractions
|
|
gptkbp:ingredients
|
C21 H27 N3 O2
|
|
gptkbp:interacts_with
|
gptkb:cimetidine
gptkb:digoxin
antihypertensives
other antiarrhythmics
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_monitored_by
|
blood pressure
ECG
renal function
liver function
|
|
gptkbp:is_used_for
|
arrhythmia
|
|
gptkbp:lifespan
|
3 to 4 hours
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
oral bioavailability 75% to 100%
|
|
gptkbp:research_areas
|
toxicology
cardiology
pharmacology
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
vomiting
rash
arrhythmias
hypotension
lupus erythematosus-like syndrome
|
|
gptkbp:traded_on
|
gptkb:Procanbid
gptkb:Pronestyl
|